A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
PRIMARY OBJECTIVES:
I. To document the toxicities, and reversibility of toxicities, of this regimen of
5-azacytidine (azacitidine) and erlotinib (erlotinib hydrochloride).
SECONDARY OBJECTIVES:
I. To determine any potential anti-tumor effects, as determined by the objective tumor
response (complete and partial responses), clinical benefit (complete and partial responses,
and clinical benefit), the time to tumor response, the time to tumor progression, and the
overall survival.